<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38652535</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2379-3708</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>23</Day></PubDate></JournalIssue><Title>JCI insight</Title><ISOAbbreviation>JCI Insight</ISOAbbreviation></Journal><ArticleTitle>Characteristics and determinants of pulmonary long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e177518</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/jci.insight.177518</ELocationID><Abstract><AbstractText>BACKGROUNDPersistent cough and dyspnea are prominent features of postacute sequelae of SARS-CoV-2 (also termed "long COVID"); however, physiologic measures and clinical features associated with these pulmonary symptoms remain poorly defined. Using longitudinal pulmonary function testing (PFT) and CT imaging, this study aimed to identify the characteristics and determinants of pulmonary long COVID.METHODSThis single-center retrospective study included 1,097 patients with clinically defined long COVID characterized by persistent pulmonary symptoms (dyspnea, cough, and chest discomfort) lasting for 1 or more months after resolution of primary COVID infection.RESULTSAfter exclusion, a total of 929 patients with post-COVID pulmonary symptoms and PFTs were stratified as diffusion impairment and pulmonary restriction, as measured by percentage predicted diffusion capacity for carbon monoxide (DLCO) and total lung capacity (TLC). Longitudinal evaluation revealed diffusion impairment (DLCO &#x2264; 80%) and pulmonary restriction (TLC &#x2264; 80%) in 51% of the cohort overall (n = 479). In multivariable modeling regression analysis, invasive mechanical ventilation during primary infection conferred the greatest increased odds of developing pulmonary long COVID with diffusion impairment and restriction (adjusted odds ratio [aOR] = 9.89, 95% CI 3.62-26.9]). Finally, a subanalysis of CT imaging identified radiographic evidence of fibrosis in this patient population.CONCLUSIONLongitudinal PFTs revealed persistent diffusion-impaired restriction as a key feature of pulmonary long COVID. These results emphasize the importance of incorporating PFTs into routine clinical practice for evaluation of long COVID patients with prolonged pulmonary symptoms. Subsequent clinical trials should leverage combined symptomatic and quantitative PFT measurements for more targeted enrollment of pulmonary long COVID patients.FUNDINGNational Institute of Allergy and Infectious Diseases (AI156898, K08AI129705), National Heart, Lung, and Blood Institute (HL153113, OTA21-015E, HL149944), and the COVID-19 Urgent Research Response Fund at the University of Alabama at Birmingham.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patton</LastName><ForeName>Michael John</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, Heersink School of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hugh Kaul Precision Medicine Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benson</LastName><ForeName>Donald</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robison</LastName><ForeName>Sarah W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raval</LastName><ForeName>Dhaval</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locy</LastName><ForeName>Morgan L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Kinner</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grumley</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levitan</LastName><ForeName>Emily B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Might</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hugh Kaul Precision Medicine Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaggar</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham VA Medical Center, Pulmonary Section, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erdmann</LastName><ForeName>Nathaniel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AI129705</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI156898</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL149944</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL153113</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCI Insight</MedlineTA><NlmUniqueID>101676073</NlmUniqueID><ISSNLinking>2379-3708</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Feb 14:2024.02.13.24302781. doi: 10.1101/2024.02.13.24302781</RefSource><PMID Version="1">38405753</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="Y">Lung</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012129" MajorTopicYN="Y">Respiratory Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003371" MajorTopicYN="N">Cough</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">Diagnostic imaging</Keyword><Keyword MajorTopicYN="N">Diagnostics</Keyword><Keyword MajorTopicYN="N">Infectious disease</Keyword><Keyword MajorTopicYN="N">Pulmonology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>22</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>23</Day><Hour>18</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>23</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38652535</ArticleId><ArticleId IdType="pmc">PMC11141907</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.177518</ArticleId><ArticleId IdType="pii">177518</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballering AV, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, et al. Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 Years &#x2014; United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(21):713&#x2013;717. doi: 10.15585/mmwr.mm7121e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934&#x2013;1946. doi: 10.1001/jama.2023.8823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747&#x2013;754. doi: 10.1016/S2213-2600(21)00174-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00174-0</ArticleId><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398(10302):747&#x2013;758. doi: 10.1016/S0140-6736(21)01755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9(11):1275&#x2013;1287. doi: 10.1016/S2213-2600(21)00383-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart I, et al. Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post-COVID-19 study. Am J Respir Crit Care Med. 2023;207(6):693&#x2013;703. doi: 10.1164/rccm.202203-0564OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202203-0564OC</ArticleId><ArticleId IdType="pmc">PMC10037479</ArticleId><ArticleId IdType="pubmed">36457159</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu JZ, et al. Lung perfusion disturbances in nonhospitalized post-COVID with dyspnea-A magnetic resonance imaging feasibility study. J Intern Med. 2022;292(6):941&#x2013;956. doi: 10.1111/joim.13558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13558</ArticleId><ArticleId IdType="pmc">PMC9539011</ArticleId><ArticleId IdType="pubmed">35946904</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, et al. One-year follow-up CT findings in COVID-19 patients: A systematic review and meta-analysis. Respirology. 2022;27(8):605&#x2013;616. doi: 10.1111/resp.14311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.14311</ArticleId><ArticleId IdType="pmc">PMC9350074</ArticleId><ArticleId IdType="pubmed">35694728</ArticleId></ArticleIdList></Reference><Reference><Citation>C-MORE/PHOSP-COVID Collaborative Group. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study. Lancet Respir Med. 2023;11(11):1003&#x2013;1019. doi: 10.1016/S2213-2600(23)00262-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00262-X</ArticleId><ArticleId IdType="pmc">PMC7615263</ArticleId><ArticleId IdType="pubmed">37748493</ArticleId></ArticleIdList></Reference><Reference><Citation>So M, et al. Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis. BMC Pulm Med. 2021;21(1):97. doi: 10.1186/s12890-021-01463-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-021-01463-0</ArticleId><ArticleId IdType="pmc">PMC7983097</ArticleId><ArticleId IdType="pubmed">33752639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, et al. &#x2018;Long-COVID&#x2019;: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396&#x2013;398. doi: 10.1136/thoraxjnl-2020-215818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, et al. Chest computed tomography and clinical follow-up of discharged patients with COVID-19 in Wenzhou City, Zhejiang, China. Ann Am Thorac Soc. 2020;17(10):1231&#x2013;1237. doi: 10.1513/AnnalsATS.202004-324OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202004-324OC</ArticleId><ArticleId IdType="pmc">PMC7640627</ArticleId><ArticleId IdType="pubmed">32692945</ArticleId></ArticleIdList></Reference><Reference><Citation>Mylvaganam RJ, et al. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev. 2021;30(162):210194. doi: 10.1183/16000617.0194-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0194-2021</ArticleId><ArticleId IdType="pmc">PMC8674935</ArticleId><ArticleId IdType="pubmed">34911696</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirmal AS, et al. Delayed lung function testing after COVID-19 to detect persistent lung function abnormalities - The DELTA - COVID-19 lung function study. J Family Med Prim Care. 2022;11(11):7351&#x2013;7356. doi: 10.4103/jfmpc.jfmpc_770_22.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_770_22</ArticleId><ArticleId IdType="pmc">PMC10041253</ArticleId><ArticleId IdType="pubmed">36993117</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockley JA, et al. Lung function and breathing patterns in hospitalised COVID-19 survivors: a review of post-COVID-19 clinics. Respir Res. 2021; 22(1):255. doi: 10.1186/s12931-021-01834-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01834-5</ArticleId><ArticleId IdType="pmc">PMC8474952</ArticleId><ArticleId IdType="pubmed">34579722</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem AM, et al. The long-term impact of COVID-19 pneumonia on the pulmonary function of survivors. Int J Gen Med. 2021;14:3271&#x2013;3280. doi: 10.2147/IJGM.S319436.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S319436</ArticleId><ArticleId IdType="pmc">PMC8276825</ArticleId><ArticleId IdType="pubmed">34267545</ArticleId></ArticleIdList></Reference><Reference><Citation>Stylemans D, et al. Evolution of lung function and chest CT 6 months after COVID-19 pneumonia: real-life data from a Belgian University Hospital. Respir Med. 2021;182:106421. doi: 10.1016/j.rmed.2021.106421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2021.106421</ArticleId><ArticleId IdType="pmc">PMC8053365</ArticleId><ArticleId IdType="pubmed">33901788</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez J, et al. Pulmonary function and radiologic features in survivors of critical COVID-19: a 3-month prospective cohort. Chest. 2021;160(1):187&#x2013;198. doi: 10.1016/j.chest.2021.02.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.02.062</ArticleId><ArticleId IdType="pmc">PMC7930807</ArticleId><ArticleId IdType="pubmed">33676998</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023;183(6):566&#x2013;580. doi: 10.1001/jamainternmed.2023.0750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Cares-Marambio K, et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Chron Respir Dis. 2021;18:14799731211002240. doi: 10.1177/14799731211002240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/14799731211002240</ArticleId><ArticleId IdType="pmc">PMC7975482</ArticleId><ArticleId IdType="pubmed">33729021</ArticleId></ArticleIdList></Reference><Reference><Citation>Herridge MS, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348(8):683&#x2013;693. doi: 10.1056/NEJMoa022450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa022450</ArticleId><ArticleId IdType="pubmed">12594312</ArticleId></ArticleIdList></Reference><Reference><Citation>Herridge MS, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293&#x2013;1304. doi: 10.1056/NEJMoa1011802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1011802</ArticleId><ArticleId IdType="pubmed">21470008</ArticleId></ArticleIdList></Reference><Reference><Citation>Masclans JR, et al. Quality of life, pulmonary function, and tomographic scan abnormalities after ARDS. Chest. 2011;139(6):1340&#x2013;1346. doi: 10.1378/chest.10-2438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.10-2438</ArticleId><ArticleId IdType="pubmed">21330382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind&#xe9;n VB, et al. ECMO in ARDS: a long-term follow-up study regarding pulmonary morphology and function and health-related quality of life. Acta Anaesthesiol Scand. 2009;53(4):489&#x2013;495. doi: 10.1111/j.1399-6576.2008.01808.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.2008.01808.x</ArticleId><ArticleId IdType="pubmed">19226296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambardar SR, et al. Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic. J Clin Med. 2021;10(11):2452. doi: 10.3390/jcm10112452.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112452</ArticleId><ArticleId IdType="pmc">PMC8199255</ArticleId><ArticleId IdType="pubmed">34205928</ArticleId></ArticleIdList></Reference><Reference><Citation>McGroder CF, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax. 2021;76(12):1242&#x2013;1245. doi: 10.1136/thoraxjnl-2021-217031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2021-217031</ArticleId><ArticleId IdType="pmc">PMC8103561</ArticleId><ArticleId IdType="pubmed">33927016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazdyrev E, et al. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals (Basel) 2021;14(8):807. doi: 10.3390/ph14080807.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14080807</ArticleId><ArticleId IdType="pmc">PMC8398080</ArticleId><ArticleId IdType="pubmed">34451904</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, et al. The immunology of long COVID. Nat Rev Immunol. 2023;23(10):618&#x2013;634. doi: 10.1038/s41577-023-00904-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, et al. A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae. Sci Transl Med. 2022;14(671):eabo5795. doi: 10.1126/scitranslmed.abo5795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo5795</ArticleId><ArticleId IdType="pubmed">36383686</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, et al. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight. 2021;6(15):e151544. doi: 10.1172/jci.insight.151544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151544</ArticleId><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021;2(1):e13&#x2013;e22. doi: 10.1016/S2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Margaroli C, et al. Spatial mapping of SARS-CoV-2 and H1N1 lung injury identifies differential transcriptional signatures. Cell Rep Med. 2021;2(4):100242. doi: 10.1016/j.xcrm.2021.100242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100242</ArticleId><ArticleId IdType="pmc">PMC7985929</ArticleId><ArticleId IdType="pubmed">33778787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, et al. Case report: pirfenidone in the treatment of post-COVID-19 pulmonary fibrosis. Front Med (Lausanne) 2022;9:925703. doi: 10.3389/fmed.2022.925703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.925703</ArticleId><ArticleId IdType="pmc">PMC9207265</ArticleId><ArticleId IdType="pubmed">35733875</ArticleId></ArticleIdList></Reference><Reference><Citation>Saiphoklang N, et al. The effect of nintedanib in post-COVID-19 lung fibrosis: an observational study. Crit Care Res Pract. 2022;2022:9972846. doi: 10.1155/2022/9972846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/9972846</ArticleId><ArticleId IdType="pmc">PMC9529527</ArticleId><ArticleId IdType="pubmed">36199668</ArticleId></ArticleIdList></Reference><Reference><Citation>Sgalla G, et al. A randomized trial of pamrevlumab in patients with COVID-19 pneumonia. Respirology. 2023;(10):954&#x2013;957. doi: 10.1111/resp.14575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.14575</ArticleId><ArticleId IdType="pubmed">37605035</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10):e2238804. doi: 10.1001/jamanetworkopen.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler, DM The costs of long COVID. JAMA Health Forum. 2022;3(5):e221809. doi: 10.1001/jamahealthforum.2022.1809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2022.1809</ArticleId><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrino R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948&#x2013;968. doi: 10.1183/09031936.05.00035205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.05.00035205</ArticleId><ArticleId IdType="pubmed">16264058</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022; 60(1):2101499. doi: 10.1183/13993003.01499-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01499-2021</ArticleId><ArticleId IdType="pubmed">34949706</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813&#x2013;1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan F, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19) Radiology. 2020;295(3):715&#x2013;721. doi: 10.1148/radiol.2020200370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020200370</ArticleId><ArticleId IdType="pmc">PMC7233367</ArticleId><ArticleId IdType="pubmed">32053470</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>